Abstract: A roast level of coffee grounds used in a coffee brewing operation may be characterized based at least in part on one or more weights of the coffee grounds determined during a grinding operation, and in some instances, may be used to determine one or more brewing parameters used in the coffee brewing operation. In addition, in some instances the roast level of the coffee grounds may be determined during a grinding operation and used to control the amount of coffee grounds generated during the grinding operation.

Abstract: The dosages and methods described herein provide desirable pharmacokinetic (PK) and pharmacodynamics (PD) characteristics which inhibit alternative pathway complement activity, for example at least 85% or more inhibition of AP activity in vivo at dosages from about 120 mg to 200 mg BID that provides a plasma level Ctrough at least about 65 ng/ml, which provides sufficient AP inhibition to reduce the risk of complement breakthrough. In addition, the dosage form described herein provides a significantly low Cmax, providing additional safety margin and better dosing flexibility.

Abstract: The present invention discloses a ferroelectric helical liquid crystal material and a method for realizing second harmonic enhancement therefor. By means of the method, a ferroelectric helical liquid crystal with an ultrahigh polarity helical structure is obtained by doping chiral molecules with ferroelectric nematic phase liquid crystals, and a dielectric constant of the ferroelectric helical liquid crystal is 104. This type of liquid crystal material has a superstrong nonlinear optical effect and can excite high-intensity second harmonic waves (for example, a nonlinear coefficient of the liquid crystal material is equivalent to that of a LiNbO3 nonlinear (NLO) crystalline material). Based on adjustability of a periodical helical structure of the ferroelectric helical liquid crystal, a molecular pitch of the ferroelectric helical liquid crystal is tuned by means of a concentration of chiral molecules (i.e., a polarization period is regulated).

Abstract: Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.

Abstract: A class of sulfonimide salts for solid-state electrolytes can be synthesized based on successive SNAr reactions of fluorinated phenyl sulfonimides: Fluorinated Aryl Sulfonimide Tags (FAST). The chemical and electrochemical oxidative stability of these FAST salts as well as other properties like solubility, Lewis basicity, and conductivity can be tuned by introducing different numbers and types of nucleophilic functional groups to the FAST salt scaffold.

Abstract: Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods for treating geographic atrophy secondary to age-related macular degeneration (AMD) and intermediate AMD in a subject. The methods include administering to the subject a therapeutically effective amount of a small molecule complement factor D inhibitor.

Abstract: Disclosed herein are methods for treating myasthenia gravis (MG) in a subject. The methods include administering to the subject a therapeutically effective amount of a small molecule complement factor D inhibitor.

Abstract: A roast level of coffee grounds used in a coffee brewing operation may be characterized based at least in part on one or more weights of the coffee grounds determined during a grinding operation, and in some instances, may be used to determine one or more brewing parameters used in the coffee brewing operation. In addition, in some instances the roast level of the coffee grounds may be determined during a grinding operation and used to control the amount of coffee grounds generated during the grinding operation.

Abstract: An electrochemical device includes a transition metal oxide cathode, such as LiNi0.8Co0.1Mn0.1O2, and an electrolyte. The electrolyte includes N, N-dimethyltrifluoromethane-sulfonamide (DMTMSA) and lithium bis(fluorosulfonyl)imide (LiFSI). The DMTMSA and LiFSI may be either the primary component of the electrolyte or an additive in the electrolyte. The electrochemical device may also include a graphite anode or a lithium metal anode. With a lithium metal anode, the electrochemical device has an initial specific capacity of at least 231 mAh g?1. Over at least 100 cycles (upper cut-off voltage of 4.7±0.05 V vs. Li/Li+), the electrochemical device maintains an average specific capacity of at least 88% of the initial specific capacity and an average Coulombic efficiency of at least about 99.65%.

Abstract: The present invention discloses an ultra-high-polarity chiral liquid crystal material, a liquid crystal laser and a preparation method therefor. The ultra-high-polarity chiral liquid crystal material has, in a certain temperature range, a high dielectric constant of ?˜104 and a characteristic of extremely-strong second harmonic response 3 to 10 times as much as that of a quartz crystal, and a pitch of the ultra-high-polarity chiral liquid crystal material is adjusted within 0.1 to 1 micrometer according to a doped concentration of the chiral molecule.

Abstract: A class of sulfonimide salts for solid-state electrolytes can be synthesized based on successive SNAr reactions of fluorinated phenyl sulfonimides: Fluorinated Aryl Sulfonimide Tags (FAST). The chemical and electrochemical oxidative stability of these FAST salts as well as other properties like solubility, Lewis basicity, and conductivity can be tuned by introducing different numbers and types of nucleophilic functional groups to the FAST salt scaffold.

Abstract: Provided are methods for treating paroxysmal nocturnal hemoglobinuria in a subject who previously exhibited an inadequate response to an anti-C5 antibody therapy, by administering to the subject a therapeutically effective amount of an inhibitor of the alternative pathway of complement (e.g., one which inhibits a target upstream to complement 5 (C5), such as Factor D or complement 3 (C3)). Also provided herein are methods for treating PNH in a human subject, comprising administering to the subject a complement factor D inhibitor alone or in combination with an anti-C5 antibody, or antigen binding fragment thereof. In some embodiments, the patient previously exhibited an inadequate response to an anti-C5 antibody therapy.

Abstract: This disclosure provides an ocular tissue depot of a selected complement factor D (CFD) inhibitor for the extended treatment of an ocular disorder mediated by complement factor D. In particular, the disclosure includes the creation of a drug depot within the choroid-retina pigmented epithelium (C-RPE) and/or the iris-ciliary body (I-CB) of the eye by means of the systemic (oral or parenteral) administration of the compound, where the compound accumulates in ocular tissue and is released over an extended period for the treatment of a posterior and/or anterior eye disorder.

Abstract: A class of sulfonimide salts for solid-state electrolytes can be synthesized based on successive SNAr reactions of fluorinated phenyl sulfonimides: Fluorinated Aryl Sulfonimide Tags (FAST). The chemical and electrochemical oxidative stability of these FAST salts as well as other properties like solubility, Lewis basicity, and conductivity can be tuned by introducing different numbers and types of nucleophilic functional groups to the FAST salt scaffold.

Abstract: A metal-oxygen battery can provide improved energy storage and transportation applications due to high gravimetric energies, and such a metal-oxygen battery can include a polyolefin including a plurality of functional groups such as sulfamide, sulfoxy, carbonyl, phosphoramide or heterocyclic groups.

Abstract: A polymer compound including a repeating unit represented by Formula: wherein R1, R2, R3, R4, a1, a2, and a11 in Formula 1 are as defined in the specification.

Abstract: Electrolytes and polymers for a lithium battery can include a fluorinated aryl sulfonimide salt or fluorinated aryl sulfonimide polymer.

Abstract: The dosages and methods described herein provide desirable pharmacokinetic (PK) and pharmacodynamics (PD) characteristics which inhibit alternative pathway complement activity, for example at least 85% or more inhibition of AP activity in vivo at dosages from about 120 mg to 200 mg BID that provides a plasma level Ctrough at least about 65 ng/ml, which provides sufficient AP inhibition to reduce the risk of complement breakthrough. In addition, the dosage form described herein provides a significantly low Cmax, providing additional safety margin and better dosing flexibility.

Abstract: Methods, compositions, reagents, and systems that allow for the preparation and utilization of sulfonamide salt polymer electrolytes are disclosed herein. Methods and reagents to prepare sulfonamide salt monomers are also disclosed herein. The sulfonamide salt polymer electrolytes can be used as components in energy storage devices, conductive materials, electrochemical cells, gels, adhesives, and drug delivery vehicles.